ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.
- This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.
- Any funding beyond the initial $4.9 million is at the sole discretion of CARB-X and subject to available funds.
- At ContraFect, we remain committed to developing superior therapeutic agents with the potential to improve clinical outcomes and save lives.
- Invasive P. aeruginosa infections, including ventilator-associated pneumonia, blood stream infections, complicated urinary tract infections, and infections following surgery carry some of the highest rates of mortality among hospital acquired infections.